Results 21 to 30 of about 17,271 (194)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer

open access: yesFrontiers in Endocrinology, 2023
BackgroundStudies using novel antiandrogens (NAA) in patients with metastatic castration-resistant prostate cancer (mCRPC) have shown overall survival benefit.
Xiangyu Chen   +7 more
doaj   +1 more source

Biotransformation of Abiraterone Into Five Characteristic Metabolites by the Rat Gut Microbiota and Liver Microsomes

open access: yesFrontiers in Oncology, 2022
It is well known that the role of gut microbiota in drug metabolism, especially in oral difficult absorbable drugs. Understanding the gut microbiota could enable us to understand drugs in new ways.
Adili Keranmu   +7 more
doaj   +1 more source

Abiraterone Acetate [PDF]

open access: yesDrugs in R&D, 2010
Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers. As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line ...
openaire   +3 more sources

Role of abiraterone acetate in the management of metastatic prostate cancer [PDF]

open access: yesBatna Journal of Medical Sciences, 2023
Objective. to analyze the clinical, biological and histological profile of patients with prostate cancer and to assess the efficacy and safety of abiraterone acetate. Patients and methods.
Wafa Bechairia
doaj   +1 more source

Abiraterone in metastatic prostate cancer without previous chemotherapy [PDF]

open access: yes, 2013
Contains fulltext : 118780.pdf (Publisher’s version ) (Open Access)BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after ...
Suttmann, Henrik   +90 more
core   +3 more sources

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation

open access: yesBiomedicines, 2022
Abiraterone is a selective inhibitor of androgen biosynthesis approved for the treatment of metastatic patients affected by castration-resistant or castration-sensitive prostate cancer.
Michele Iuliani   +7 more
doaj   +1 more source

CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2 [PDF]

open access: yes, 2017
Abiraterone is an inhibitor of CYP17A1 which is used for the treatment of castration resistant prostate cancer. Abiraterone is known to inhibit several drug metabolizing cytochrome P450 enzymes including CYP1A2, CYP2D6, CYP2C8, CYP2C9, CYP2C19, CYP3A4 ...
Brixius-Anderko, Simone   +20 more
core   +4 more sources

Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database [PDF]

open access: yesCancer Med
This real‐world study of the Flatiron Health database found that first‐line treatment with abiraterone versus enzalutamide was associated with significantly shorter overall survival, treatment duration, and time to subsequent treatment in patients with chemotherapy‐ and androgen receptor pathway inhibitor‐naïve metastatic castration‐resistant prostate ...
George D   +8 more
europepmc   +2 more sources

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. [PDF]

open access: yes, 2013
BACKGROUND: Standard medical castration reduces muscle mass. We sought to characterize body composition changes in men undergoing maximal androgen suppression with and without exogenous gluocorticoids.
J S de Bono   +32 more
core   +1 more source

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling [PDF]

open access: yes, 2021
INTRODUCTION: Castration‐resistant prostate cancer (CRPC) remains dependent on androgen receptor (AR) signalling, which is largely driven by conversion of adrenal androgen precursors lasting after castration.
Guido W. Jenster   +30 more
core   +1 more source

Home - About - Disclaimer - Privacy